A newly published study from Israel has raised serious concerns over finasteride, one of the most commonly prescribed medications for androgenetic alopecia (male pattern baldness). The research suggests that long-term users of finasteride are at a statistically higher risk of mood disorders, depression, and suicidal thoughts compared to non-users, prompting calls for more caution in its medical use.

The lead investigator, Dr. Mayer Brezis of the Hadassah-Hebrew University Medical Center, and his team analyzed global adverse event reports, medical literature, and health records to identify patterns. They found that although warnings on depression have been included in the drug’s labeling since 2011, and suicidal ideation was formally added only in 2022, evidence of psychiatric risk had been emerging as early as the early 2000s.

Key Findings and Insights

• Stronger psychiatric signal: The study reports that individuals on finasteride had a higher incidence of depression, anxiety, and suicidal tendencies than control groups, even after accounting for other risk factors.
• Delayed regulatory response: Internal documents suggest that regulatory bodies were alerted to possible suicidal risk decades ago, but definitive label changes were slow to follow.
• Mechanistic speculation: Though the study does not conclusively pinpoint a biological mechanism, the authors hypothesize that alterations in neurosteroids, inflammation, or hippocampal function may play roles in sparking psychiatric symptoms in susceptible individuals.
• Global resonance: The review emphasizes that such adverse psychiatric effects have been underreported and possibly underestimated, urging health agencies and clinicians worldwide to revisit the safety profile of finasteride.

Response from Regulators and Industry

Several drug regulatory bodies, including the European Medicines Agency (EMA), have already acknowledged a link between finasteride and suicidal thoughts, particularly at the low 1 mg dosage used for hair loss. The EMA’s safety review confirmed that suicidal ideation should be recognized as a documented adverse effect of finasteride, though they maintain that for approved uses, the benefits may outweigh the risks.

Pharmaceutical companies that produce finasteride and its generics have not issued detailed public responses yet. However, the study’s publication is likely to increase pressure from patients, clinicians, and regulators to demand more transparent disclosures and stricter monitoring of psychiatric outcomes.

What This Means for Users and Clinicians

• Risk vs benefit evaluation: Patients considering finasteride—especially those with a prior psychiatric history—should discuss the risks thoroughly with their doctors.
• Monitoring is crucial: Clinicians prescribing finasteride are urged to monitor mood changes, suicidal thoughts, and signs of depression through regular follow-up.
• Informed consent: The study underscores the need for clearer, more comprehensive warnings and consent procedures covering psychiatric risks.
• Alternatives and caution: For those uneasy about these risks, alternative hair loss treatments or non-pharmaceutical approaches may be preferable.

While finasteride remains a powerful tool in managing hair loss, this study serves as a cautionary signal—not to discard the drug outright, but to handle it with greater psychiatric awareness and regulatory vigilance.